Degrees has signed a patent licence agreement with Yale School of Medicine for tafenoquine development for babesiosis.

In symptomatic patients, the main treatment for babesiosis is a combination of antiparasitic drugs and antibiotics. The latter drugs are primarily used to treat bacterial infections, rather than ...

Tafenoquine is not currently approved by the U.S. Food and Drug Administration (“FDA”) for the treatment and prevention of babesiosis. The agreement follows initiation of collaboration between ...

Degrees Pharmaceuticals (SXTP) announced the signing of a Patent License Agreement with Yale School of Medicine and Yale School of Public ...

Ticks are tiny, spider-like creatures which feed on the blood of animals and humans, and are commonly found in woodland and moorland ...

"Babesiosis has been rising in prevalence,” said Dr. Dow. "Yet public and clinical recognition of the existence and ...

Get Instant Summarized Text (Gist) Bartonella henselae and two Babesia species, B. odocoilei and B. divergens-like MO-1, were detected in the brain tissue of a child with seizures and suspected ...

Although tafenoquine is approved in the US for malaria prophylaxis under the name Arakoda, its effectiveness for babesiosis treatment or prevention has not yet been established in the country.